These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 20690341)

  • 1. More allopurinol is needed to get gout patients < 0.36 mmol/l: a gout audit in the form of a before-after trial.
    Arroll B; Bennett M; Dalbeth N; Hettiarachchi D; Ben C; Shelling G
    J Prim Health Care; 2009 Dec; 1(4):315-8. PubMed ID: 20690341
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dose adjustment of allopurinol according to creatinine clearance does not provide adequate control of hyperuricemia in patients with gout.
    Dalbeth N; Kumar S; Stamp L; Gow P
    J Rheumatol; 2006 Aug; 33(8):1646-50. PubMed ID: 16783857
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Allopurinol for chronic gout.
    Seth R; Kydd AS; Buchbinder R; Bombardier C; Edwards CJ
    Cochrane Database Syst Rev; 2014 Oct; 2014(10):CD006077. PubMed ID: 25314636
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Allopurinol adherence among patients with gout: an Italian general practice database study.
    Mantarro S; Capogrosso-Sansone A; Tuccori M; Blandizzi C; Montagnani S; Convertino I; Antonioli L; Fornai M; Cricelli I; Pecchioli S; Cricelli C; Lapi F
    Int J Clin Pract; 2015 Jul; 69(7):757-65. PubMed ID: 25683693
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Modifiable factors associated with allopurinol adherence and outcomes among patients with gout in an integrated healthcare system.
    Rashid N; Coburn BW; Wu YL; Cheetham TC; Curtis JR; Saag KG; Mikuls TR
    J Rheumatol; 2015 Mar; 42(3):504-12. PubMed ID: 25512479
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The challenges of managing gout in primary care: Results of a best-practice audit.
    Stamp LK; Chapman P; Hudson B; Frampton C; Hamilton G; Judd A
    Aust J Gen Pract; 2019 Sep; 48(9):631-637. PubMed ID: 31476837
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Quality of care in gout: a clinical audit on treating to the target with urate lowering therapy in real-world gout patients.
    Janssen CA; Jansen TLTA; Oude Voshaar MAH; Vonkeman HE; van de Laar MAFJ
    Rheumatol Int; 2017 Sep; 37(9):1435-1440. PubMed ID: 28748426
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The optimal use of allopurinol: an audit of allopurinol use in South Auckland.
    Stamp L; Gow P; Sharples K; Raill B
    Aust N Z J Med; 2000 Oct; 30(5):567-72. PubMed ID: 11108066
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Understanding and improving the use of allopurinol in a teaching hospital.
    Hmar RC; Kannangara DR; Ramasamy SN; Baysari MT; Williams KM; Day RO
    Intern Med J; 2015 Apr; 45(4):383-90. PubMed ID: 25644128
    [TBL] [Abstract][Full Text] [Related]  

  • 10. African American patients with gout: efficacy and safety of febuxostat vs allopurinol.
    Wells AF; MacDonald PA; Chefo S; Jackson RL
    BMC Musculoskelet Disord; 2012 Feb; 13():15. PubMed ID: 22316106
    [TBL] [Abstract][Full Text] [Related]  

  • 11. As compared to allopurinol, urate-lowering therapy with febuxostat has superior effects on oxidative stress and pulse wave velocity in patients with severe chronic tophaceous gout.
    Tausche AK; Christoph M; Forkmann M; Richter U; Kopprasch S; Bielitz C; Aringer M; Wunderlich C
    Rheumatol Int; 2014 Jan; 34(1):101-9. PubMed ID: 24026528
    [TBL] [Abstract][Full Text] [Related]  

  • 12. An open-label, 6-month study of allopurinol safety in gout: The LASSO study.
    Becker MA; Fitz-Patrick D; Choi HK; Dalbeth N; Storgard C; Cravets M; Baumgartner S
    Semin Arthritis Rheum; 2015 Oct; 45(2):174-83. PubMed ID: 26190562
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A Real-World Study of Switching From Allopurinol to Febuxostat in a Health Plan Database.
    Altan A; Shiozawa A; Bancroft T; Singh JA
    J Clin Rheumatol; 2015 Dec; 21(8):411-8. PubMed ID: 26580304
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A world of hurt: failure to achieve treatment goals in patients with gout requires a paradigm shift.
    Khanna P; Khanna D; Storgard C; Baumgartner S; Morlock R
    Postgrad Med; 2016 Jan; 128(1):34-40. PubMed ID: 26578028
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Lesinurad in combination with allopurinol: a randomised, double-blind, placebo-controlled study in patients with gout with inadequate response to standard of care (the multinational CLEAR 2 study).
    Bardin T; Keenan RT; Khanna PP; Kopicko J; Fung M; Bhakta N; Adler S; Storgard C; Baumgartner S; So A
    Ann Rheum Dis; 2017 May; 76(5):811-820. PubMed ID: 27821644
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Gout in the UK and Germany: prevalence, comorbidities and management in general practice 2000-2005.
    Annemans L; Spaepen E; Gaskin M; Bonnemaire M; Malier V; Gilbert T; Nuki G
    Ann Rheum Dis; 2008 Jul; 67(7):960-6. PubMed ID: 17981913
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Achieving serum urate goal: a comparative effectiveness study between allopurinol and febuxostat.
    Hatoum H; Khanna D; Lin SJ; Akhras KS; Shiozawa A; Khanna P
    Postgrad Med; 2014 Mar; 126(2):65-75. PubMed ID: 24685969
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Achievement of the target serum urate level among patients with gout treated with allopurinol or febuxostat in an arthritis clinic in the Philippines.
    Quilisadio JEC; Salido EO; Penserga EG
    Mod Rheumatol; 2021 May; 31(3):755-761. PubMed ID: 32701037
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prescription and dosing of urate-lowering therapy, rather than patient behaviours, are the key modifiable factors associated with targeting serum urate in gout.
    Dalbeth N; House ME; Horne A; Petrie KJ; McQueen FM; Taylor WJ
    BMC Musculoskelet Disord; 2012 Sep; 13():174. PubMed ID: 22978848
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Facilitating equitable prevention and management of gout for Māori in Northland, New Zealand, through a collaborative primary care approach.
    Lawrence A; Scott S; Saparelli F; Greville G; Miller A; Taylor A; Gow P
    J Prim Health Care; 2019 Jul; 11(2):117-127. PubMed ID: 32171354
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.